Reckitt Benckiser Shares Surge to New High; Analysts Weigh In

Reckitt Benckiser Group plc achieved a significant milestone on Tuesday, with its stock price reaching a new 52-week high. The shares traded at a peak of GBX 6,094 during the session, closing at the same price after approximately 4,555,683 shares changed hands. This marks an increase from the previous closing price of GBX 5,988.

Analysts have been actively weighing in on the stock, providing varying outlooks. On October 17, 2023, UBS Group reaffirmed a “buy” rating, setting a price target of GBX 7,700 for Reckitt Benckiser shares. Meanwhile, JPMorgan Chase & Co. raised their target from GBX 5,500 to GBX 6,100 in a report dated November 26, 2023, maintaining a “neutral” rating.

Other notable evaluations include Deutsche Bank Aktiengesellschaft, which increased its target from GBX 5,600 to GBX 5,700 and issued a “buy” rating on October 24, 2023. Additionally, Royal Bank Of Canada adjusted its price objective from GBX 6,000 to GBX 6,400, rating the stock as “outperform” as of October 23, 2023. Jefferies Financial Group took a more cautious approach, maintaining a “hold” rating with a target price of GBX 5,200 on October 2, 2023.

Currently, three analysts classify Reckitt Benckiser shares as a “buy,” while three others have assigned a “hold” rating. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of approximately GBX 6,109.17.

Insider Activity and Company Overview

In related news, insider Patricia Verduin made a notable purchase of 135 shares on October 29, 2023, acquiring them at an average price of GBX 5,867 per share. The total value of this transaction was approximately £7,920.45, and insiders currently hold about 0.42% of the company’s stock.

Reckitt Benckiser is a prominent player in the health and hygiene sector, known for its portfolio of well-established consumer brands. The company emphasizes its commitment to delivering solutions that enhance the quality of life for consumers around the globe. Brands such as Dettol, Lysol, Durex, and Nurofen form part of its extensive offering, which has been trusted by families for over 200 years. With over 30 million products sold daily, Reckitt’s reach is substantial, supported by its scientific expertise and understanding of consumer needs.

As the company continues to attract attention from analysts and investors alike, its recent stock performance raises questions about future growth and market positioning.